Exploring 3 Undervalued Small Caps With Insider Activity Across Regions

In This Article:

In recent weeks, global markets have been marked by volatility and sector-specific movements as investors react to the incoming Trump administration's policy signals and economic data, such as inflation rates and interest rate expectations. The S&P 600 for small-cap stocks has experienced fluctuations amid these broader market sentiments, highlighting the potential opportunities within this segment for those looking to navigate current economic uncertainties. In this context, identifying small-cap stocks with strong fundamentals and notable insider activity can be a strategic approach for investors seeking value in today's dynamic environment.

Top 10 Undervalued Small Caps With Insider Buying

Name

PE

PS

Discount to Fair Value

Value Rating

Paradeep Phosphates

24.0x

0.8x

28.70%

★★★★★☆

Thryv Holdings

NA

0.7x

48.16%

★★★★★☆

Capital Bancorp

14.4x

3.0x

47.12%

★★★★☆☆

Avia Avian

16.4x

3.8x

10.30%

★★★★☆☆

NCL Industries

15.0x

0.5x

-83.38%

★★★☆☆☆

Semen Indonesia (Persero)

20.7x

0.7x

29.75%

★★★☆☆☆

L.G. Balakrishnan & Bros

13.5x

1.6x

-34.62%

★★★☆☆☆

Tai Sin Electric

12.1x

0.4x

15.75%

★★★☆☆☆

Community West Bancshares

18.7x

2.9x

42.25%

★★★☆☆☆

Genus

136.7x

1.6x

29.51%

★★★☆☆☆

Click here to see the full list of 176 stocks from our Undervalued Small Caps With Insider Buying screener.

Let's dive into some prime choices out of from the screener.

Shalby

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Shalby operates primarily in the healthcare sector, providing healthcare services and manufacturing implants, with a market capitalization of ₹13.25 billion.

Operations: Shalby generates revenue primarily from healthcare services and the manufacturing of implants, with healthcare services contributing significantly more. The company's cost structure is dominated by the cost of goods sold (COGS), which affects its gross profit margin. Over recent periods, the gross profit margin has shown variability, reaching as high as 28.44% in June 2024 and dropping to 24.39% by September 2024.

PE: 42.4x

Shalby, operating in a dynamic healthcare sector, presents itself as a potentially undervalued opportunity. Recent earnings showed sales growth to INR 2,675.39 million for Q2 2024 from INR 2,379.84 million the previous year, though net income fell significantly to INR 33.94 million from INR 275.83 million. Despite this dip in profitability and reliance on external borrowing for funding, insider confidence is evident with recent share purchases by executives over the past months. The company’s forecasted earnings growth rate of nearly 60% annually suggests potential upside if operational efficiencies improve and external conditions stabilize further enhancing its small-cap appeal amidst market volatility.